E. Magnus Ohman, MD: Hello. I'm Magnus Ohman, and welcome to another edition of the Life and Times of Leading Cardiologists. I'm very fortunate today to have a leader of cardiovascular medicine, Professor Rory Collins from the University of Oxford. He has been behind the science we use every day in our practice: reperfusion therapy, thrombolysis, aspirin, blood pressure control, long-term use of aspirin, and statins—really, all the facets of medicine that we use now. Welcome.
Rory E. Collins MBBS, MSc: Thanks a lot, Magnus.
Knighthood
Dr Ohman: Rob Califf started this series some years ago, but you are the first person we have had on who has been knighted by the Queen. You are supposed to be called Sir Rory, but can I just call you Rory?
Dr Collins: Yes, I think so. It's an American program.
Dr Ohman: We recognize that, but tell me more. How did knighting come about? It does not happen every day.
Dr Collins: I received it for services to science, but really, it was for digging the funders out of a hole. They had funded a concept of establishing a very large, prospective cohort of half a million people in Britain, the UK Biobank Cohort, but they did not know how to make it happen.
Pediatric Thromboembolism
Thromboembolism in Pregnancy
COMMENTARY
Life and Times of Leading Cardiologists: Rory Collins
E. Magnus Ohman, MD; Rory E. Collins, MBBS, MSc
DisclosuresOctober 02, 2017
E. Magnus Ohman, MD: Hello. I'm Magnus Ohman, and welcome to another edition of the Life and Times of Leading Cardiologists. I'm very fortunate today to have a leader of cardiovascular medicine, Professor Rory Collins from the University of Oxford. He has been behind the science we use every day in our practice: reperfusion therapy, thrombolysis, aspirin, blood pressure control, long-term use of aspirin, and statins—really, all the facets of medicine that we use now. Welcome.
Rory E. Collins MBBS, MSc: Thanks a lot, Magnus.
Knighthood
Dr Ohman: Rob Califf started this series some years ago, but you are the first person we have had on who has been knighted by the Queen. You are supposed to be called Sir Rory, but can I just call you Rory?
Dr Collins: Yes, I think so. It's an American program.
Dr Ohman: We recognize that, but tell me more. How did knighting come about? It does not happen every day.
Dr Collins: I received it for services to science, but really, it was for digging the funders out of a hole. They had funded a concept of establishing a very large, prospective cohort of half a million people in Britain, the UK Biobank Cohort, but they did not know how to make it happen.
© 2017 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: E. Magnus Ohman, Rory E. Collins. Life and Times of Leading Cardiologists: Rory Collins - Medscape - Oct 02, 2017.
Tables
References
Authors and Disclosures
Authors and Disclosures
Author(s)
E. Magnus Ohman, MD
Professor of Medicine, Division of Cardiovascular Medicine; Vice-Chair, Department of Medicine, Development and Innovation; Kent and Siri Rawson Director, Duke Program for Advanced Coronary Disease; Associate Director, Duke Heart Center, Duke University Medical Center, Durham, North Carolina
Disclosure: E. Magnus Ohman, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Abbott Vascular; ABIOMED; AstraZeneca Pharmaceuticals LP; Biotie Therapies; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo; Faculty Connection, LLC; Merck & Co; St. Jude Medical; Stealth Peptides; The Medicines Company; Medscape
Received research grant from: Daiichi Sankyo; Gilead Sciences Inc; Janssen Pharmaceutical Products, LP
Received income in an amount equal to or greater than $250 from: ABIOMED; AstraZeneca Pharmaceuticals LP; Biotie Therapies; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo; Faculty Connection, LLC; Gilead Sciences Inc; Janssen Pharmaceutical Products, LP; Stealth Peptides; The Medicines Company; Medscape
Rory E. Collins, MBBS, MSc
Professor, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
Disclosure: Rory E. Collins, MBBS, MSc, has disclosed the following relevant financial relationships:
Serve(d) as CEO for: UK Biobank
Received research grant from: Merck & Co., Inc.